{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:14:14Z","timestamp":1790194454088,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013302","name":"KAIMRC","doi-asserted-by":"crossref","award":["SP22R\/239\/09"],"award-info":[{"award-number":["SP22R\/239\/09"]}],"id":[{"id":"10.13039\/501100013302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13345-9","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:30:00Z","timestamp":1734928200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Tariq","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Alsubait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshari","family":"Aloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghala","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama I.","family":"Alwassil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad J.","family":"Obaidullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar S.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"13345_CR1","doi-asserted-by":"crossref","unstructured":"Carling T, Udelsman R. Thyroid Cancer. 2014;65:125\u201337. https:\/\/doi.org\/101146\/annurev-med-061512-105739. Available from: https:\/\/www.annualreviews.org\/doi\/abs\/10.1146\/annurev-med-061512-105739.\u00a0[cited 2023 Sep 18].","DOI":"10.1146\/annurev-med-061512-105739"},{"issue":"1","key":"13345_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/ol.2010.223","volume":"2","author":"M Stamatakos","year":"2011","unstructured":"Stamatakos M, Paraskeva P, Stefanaki C, Katsaronis P, Lazaris A, Safioleas K, et al. Medullary thyroid carcinoma: The third most common thyroid cancer reviewed. Oncol Lett. 2011;2(1):49. Available from: https:\/\/www.spandidos-publications.com\/10.3892\/ol.2010.223.","journal-title":"Oncol Lett"},{"key":"13345_CR3","doi-asserted-by":"crossref","unstructured":"Jannin A, Escande A, Al Ghuzlan A, et al. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel). 2022;14(4). Available from: https:\/\/www.mdpi.com\/2072-6694\/14\/4\/1061.","DOI":"10.3390\/cancers14041061"},{"issue":"3","key":"13345_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2020","unstructured":"Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2020;17(3):176\u201388.\u00a0Available from: https:\/\/www.nature.com\/articles\/s41574-020-00448-z.\u00a0[cited 2023 Sep 18].","journal-title":"Nat Rev Endocrinol"},{"key":"13345_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-319-22542-5_2","volume":"204","author":"KW Schmid","year":"2015","unstructured":"Schmid KW. Histopathology of C Cells and Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015;204:41\u201360.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26494383\/. [cited 2023 Sep 18].","journal-title":"Recent Results Cancer Res."},{"issue":"10","key":"13345_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","volume":"18","author":"M Roy","year":"2013","unstructured":"Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18(10):1093\u2013100.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24037980\/. [cited 2023 Sep 18].","journal-title":"Oncologist."},{"issue":"6","key":"13345_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/thy.2005.15.531","volume":"15","author":"MA Kouvaraki","year":"2005","unstructured":"Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531\u201344.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16029119\/.\u00a0[cited 2023 Oct 6].","journal-title":"Thyroid."},{"issue":"4\u20135","key":"13345_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","volume":"16","author":"E Arighi","year":"2005","unstructured":"Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4\u20135):441\u201367.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15982921\/. [cited 2023 Sep 18].","journal-title":"Cytokine Growth Factor Rev."},{"issue":"38","key":"13345_CR9","doi-asserted-by":"publisher","first-page":"35808","DOI":"10.1074\/jbc.M104968200","volume":"276","author":"J Anders","year":"2001","unstructured":"Anders J, Kj\u00e6r S, Ib\u00e1\u00f1ez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem. 2001;276(38):35808\u201317.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11445581\/.\u00a0[cited 2023 Sep 18].","journal-title":"J Biol Chem."},{"issue":"3","key":"13345_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1210\/jc.2014-4153","volume":"100","author":"EG Grubbs","year":"2015","unstructured":"Grubbs EG, Ng PKS, Bui J, Busaidy NL, Chen K, Lee JE, et al. RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2015;100(3):788\u201393. https:\/\/doi.org\/10.1210\/jc.2014-4153. [cited 2023 Sep 22].","journal-title":"J Clin Endocrinol Metab."},{"key":"13345_CR11","doi-asserted-by":"crossref","unstructured":"Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, et al. Update on Targeted Therapy in Medullary Thyroid Cancer. Front Endocrinol (Lausanne). 2021;12. Available from: https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2021.708949\/full.","DOI":"10.3389\/fendo.2021.708949"},{"issue":"4","key":"13345_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","volume":"12","author":"C Romei","year":"2016","unstructured":"Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192\u2013202.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"13345_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1349-7006.2005.00023.x","volume":"96","author":"Y Kodama","year":"2005","unstructured":"Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96(3):143\u20138.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15771616\/. [cited 2023 Sep 20].","journal-title":"Cancer Sci."},{"issue":"28","key":"13345_CR14","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.2217\/fon-2022-0657","volume":"18","author":"LJ Wirth","year":"2022","unstructured":"Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, et al. LIBRETTO-531: A phase III study of selpercatinib in multikinase inhibitor-na\u00efve RET-mutant medullary thyroid cancer. Future Oncol. 2022;18(28):3143\u201350.\u00a0Available from: https:\/\/www.futuremedicine.com\/doi\/10.2217\/fon-2022-0657. [cited 2023 Sep 18].","journal-title":"Future Oncol."},{"issue":"29","key":"13345_CR15","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639\u201346.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13345_CR16","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/ijms24032312","volume":"24","author":"L H\u00f8jer Wang","year":"2023","unstructured":"H\u00f8jer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int J Mol Sci. 2023;24(3):2312.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"13345_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.2011.37.8638","volume":"30","author":"B Solomon","year":"2012","unstructured":"Solomon B, Rischin D. Progress in molecular targeted therapy for thyroid cancer: Vandetanib in medullary thyroid cancer. J Clin Oncol. 2012;30(2):119\u201321.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13345_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134\u201341.","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"13345_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0378-1119(00)00302-4","volume":"256","author":"SD Andrew","year":"2000","unstructured":"Andrew SD, Delhanty PJD, Mulligan LM, Robinson BG. Sp1 and Sp3 transactivate the RET proto-oncogene promoter. Gene. 2000;256(1\u20132):283\u201391.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11054558\/.\u00a0[cited 2023 Sep 22].","journal-title":"Gene."},{"issue":"1","key":"13345_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0378-1119(02)00919-8","volume":"298","author":"SD Andrew","year":"2002","unstructured":"Andrew SD, Capes-Davis A, Delhanty PJD, Marsh DJ, Mulligan LM, Robinson BG. Transcriptional repression of the RET proto-oncogene by a mitogen activated protein kinase-dependent signalling pathway. Gene. 2002;298(1):9\u201319.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12406571\/.\u00a0[cited 2023 Sep 22].","journal-title":"Gene."},{"issue":"8","key":"13345_CR21","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1093\/nar\/gkn078","volume":"36","author":"AK Todd","year":"2008","unstructured":"Todd AK, Neidle S. The relationship of potential G-quadruplex sequences in cis-upstream regions of the human genome to SP1-binding elements. Nucleic Acids Res. 2008;36(8):2700\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18353860\/.\u00a0[cited 2023 Sep 22].","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"13345_CR22","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.1093\/nar\/15.19.8069","volume":"15","author":"JG Mccarthy","year":"1987","unstructured":"Mccarthy JG, Heywood SM. A long polypyrimidine\/polypurine tract induces an altered DNA conformation on the 3\u2019 coding region of the adjacent myosin heavy chain gene. Nucleic Acids Res. 1987;15(19):8069. Available from: https:\/\/academic.oup.com\/nar\/article\/15\/19\/8069\/1078606?login=false .","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"13345_CR23","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1093\/nar\/gki917","volume":"33","author":"D Sun","year":"2005","unstructured":"Sun D, Guo K, Rusche JJ, Hurley LH. Facilitation of a structural transition in the polypurine\/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res. 2005;33(18):6070\u201380.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16239639\/. [cited 2023 Sep 22].","journal-title":"Nucleic Acids Res."},{"key":"13345_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nature755","volume":"6891","author":"GN Parkinson","year":"2002","unstructured":"Parkinson GN, Lee MPH, Neidle S. Crystal structure of parallel quadruplexes from human telomeric DNA. Nature. 2002;6891:876\u201380.\u00a0Available from: https:\/\/www.nature.com\/articles\/nature755.\u00a0[cited 2023 Sep 22].","journal-title":"Nature"},{"issue":"28","key":"13345_CR25","doi-asserted-by":"publisher","first-page":"8710","DOI":"10.1021\/ja048805k","volume":"126","author":"AT Phan","year":"2004","unstructured":"Phan AT, Modi YS, Patel DJ. Propeller-type parallel-stranded G-quadruplexes in the human c-myc promoter. J Am Chem Soc. 2004;126(28):8710\u20136.\u00a0Available from: https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/ja048805k. [cited 2023 Sep 22].","journal-title":"J Am Chem Soc."},{"key":"13345_CR26","doi-asserted-by":"crossref","unstructured":"Kumarasamy VM, Shin YJ, White J, Sun D. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. BMC Cancer. 2015;15(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26307103\/.\u00a0[cited 2023 Sep 19]","DOI":"10.1186\/s12885-015-1610-5"},{"issue":"2","key":"13345_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.trechm.2019.07.002","volume":"2","author":"J Spiegel","year":"2020","unstructured":"Spiegel J, Adhikari S, Balasubramanian S. The Structure and Function of DNA G-Quadruplexes. Trends Chem. 2020;2(2):123\u201336.","journal-title":"Trends Chem"},{"key":"13345_CR28","doi-asserted-by":"crossref","unstructured":"Alqahtani T, Kumarasamy V, Alghamdi SS, Suliman RS, Bin Saleh K, Alrashed MA, et al. Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes. Cancers (Basel). 2023;15(7). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37046823\/.\u00a0[cited 2023 Sep 18].","DOI":"10.3390\/cancers15072163"},{"issue":"10","key":"13345_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/onc.2014.65","volume":"34","author":"YJ Shin","year":"2015","unstructured":"Shin YJ, Kumarasamy V, Camacho D, Sun D. Involvement of G-quadruplex structures in regulation of human RET gene expression by small molecules in human medullary thyroid carcinoma TT cells. Oncogene. 2015;34(10):1292\u20139.\u00a0Available from: https:\/\/www.nature.com\/articles\/onc201465.\u00a02014 Mar 24 [cited 2023 Sep 18].","journal-title":"Oncogene"},{"key":"13345_CR30","doi-asserted-by":"crossref","unstructured":"Kaushik V, Yakisich JS, Kumar A, Azad N, Iyer AKV. Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers. Cancers (Basel). 2018;10(10). Available from: https:\/\/www.mdpi.com\/2072-6694\/10\/10\/360.","DOI":"10.3390\/cancers10100360"},{"issue":"2","key":"13345_CR31","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1039\/C6CP05324F","volume":"19","author":"B Mart\u00ednez-Haya","year":"2017","unstructured":"Mart\u00ednez-Haya B, Avil\u00e9s-Moreno JR, Hamad S, Elguero J. On the ionophoric selectivity of nonactin and related macrotetrolide derivatives. Phys Chem Chem Phys. 2017;19(2):1288\u201397.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27966685\/.\u00a0[cited 2023 Sep 18].","journal-title":"Phys Chem Chem Phys."},{"issue":"23","key":"13345_CR32","doi-asserted-by":"publisher","first-page":"14984","DOI":"10.1039\/C7CP02438J","volume":"19","author":"JR Avil\u00e9s-Moreno","year":"2017","unstructured":"Avil\u00e9s-Moreno JR, G\u00e1mez F, Berden G, Oomens J, Mart\u00ednez-Haya B. Isolated alkali cation complexes of the antibiotic ionophore nonactin: Correlation with crystalline structures. Phys Chem Chem Phys. 2017;19(23):14984\u201391.","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"13345_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1432-1033.1994.tb18973.x","volume":"223","author":"MN Borrel","year":"1994","unstructured":"Borrel MN, Pereira E, Fiallo M, Garnier-Suillerot A. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4\u2019-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. Eur J Biochem. 1994;223(1):125\u201333.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7518390\/.\u00a0[cited 2023 Sep 18].","journal-title":"Eur J Biochem."},{"issue":"11","key":"13345_CR34","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1535-7163.MCT-07-0014","volume":"6","author":"CY Xie","year":"2007","unstructured":"Xie CY, Zhu H, Lin LP, Miao ZH, Geng MY, Cai YJ, et al. MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison. Mol Cancer Ther. 2007;6(11):3059\u201370.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18025289\/.\u00a0[cited 2023 Sep 18].","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"13345_CR35","first-page":"348","volume":"56","author":"T Alqahtani","year":"2020","unstructured":"Alqahtani T, Kumarasamy VM, Huczy\u0144ski A, Sun D. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma. Int J Oncol. 2020;56(1):348\u201358.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31746350\/.\u00a0 [cited 2023 Sep 19].","journal-title":"Int J Oncol."},{"issue":"15","key":"13345_CR36","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1093\/nar\/gkr233","volume":"39","author":"X Tong","year":"2011","unstructured":"Tong X, Lan W, Zhang X, Wu H, Liu M, Cao C. Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence. Nucleic Acids Res. 2011;39(15):6753\u201363.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21540209\/.\u00a0[cited 2023 Sep 19].","journal-title":"Nucleic Acids Res."},{"issue":"31","key":"13345_CR37","doi-asserted-by":"publisher","first-page":"49649","DOI":"10.18632\/oncotarget.10105","volume":"7","author":"A Lopergolo","year":"2016","unstructured":"Lopergolo A, Perrone R, Tortoreto M, Doria F, Beretta GL, Zuco V, et al. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer. Oncotarget. 2016;7(31):49649. Available from:\u00a0https:\/\/www.oncotarget.com\/article\/10105\/text\/ .","journal-title":"Oncotarget"},{"issue":"4","key":"13345_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","volume":"60","author":"M Grieco","year":"1990","unstructured":"Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557\u201363.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/2406025\/.\u00a0[cited 2023 Sep 19].","journal-title":"Cell."},{"issue":"6126","key":"13345_CR39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/328170a0","volume":"328","author":"A Fusco","year":"1987","unstructured":"Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987;328(6126):170\u20132.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3600795\/.\u00a0[cited 2023 Sep 19].","journal-title":"Nature."},{"issue":"1","key":"13345_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/EP:13:1:03","volume":"13","author":"YE Nikiforov","year":"2002","unstructured":"Nikiforov YE. RET\/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3\u201316.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12114746\/.\u00a0[cited 2023 Sep 19].","journal-title":"Endocr Pathol."},{"issue":"14","key":"13345_CR41","first-page":"3727","volume":"60","author":"G De Vita","year":"2000","unstructured":"De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res. 2000;60(14):3727\u201331.","journal-title":"Cancer Res"},{"key":"13345_CR42","doi-asserted-by":"crossref","unstructured":"Regua AT, Najjar M, Lo HW. RET signaling pathway and RET inhibitors in human cancer. Front Oncol. 2022;12.\u00a0Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35957881.\u00a0[cited 2023 Sep 19].","DOI":"10.3389\/fonc.2022.932353"},{"issue":"5","key":"13345_CR43","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1074\/jbc.275.5.3568","volume":"275","author":"C Segouffin-Cariou","year":"2000","unstructured":"Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase\/AKT signaling pathway. J Biol Chem. 2000;275(5):3568\u201376.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10652352\/.\u00a0[cited 2023 Sep 19].","journal-title":"J Biol Chem."},{"issue":"5","key":"13345_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1101\/gad.7.5.812","volume":"7","author":"V Baldin","year":"1993","unstructured":"Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812\u201321.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8491378\/.\u00a0[cited 2023 Sep 19].","journal-title":"Genes Dev."},{"issue":"7","key":"13345_CR45","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1128\/MCB.15.7.3463","volume":"15","author":"D Resnitzky","year":"1995","unstructured":"Resnitzky D, Reed SI. Different Roles for Cyclins D1 and E in Regulation of the G 1 -to-S Transition. Mol Cell Biol. 1995;15(7):3463\u20139.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"13345_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","volume":"3","author":"Y Tsujimoto","year":"1998","unstructured":"Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3(11):697\u2013707.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9990505\/.\u00a0 [cited 2023 Sep 19].","journal-title":"Genes Cells."},{"issue":"9","key":"13345_CR47","doi-asserted-by":"publisher","first-page":"22989","DOI":"10.3390\/ijms160922989","volume":"16","author":"H Guo","year":"2015","unstructured":"Guo H, Cui H, Peng X, Fang J, Zuo Z, Deng J, et al. Modulation of the PI3K\/Akt Pathway and Bcl-2 Family Proteins Involved in Chicken\u2019s Tubular Apoptosis Induced by Nickel Chloride (NiCl2). Int J Mol Sci. 2015;16(9):22989. Available from: https:\/\/www.mdpi.com\/1422-0067\/16\/9\/22989.","journal-title":"Int J Mol Sci."},{"issue":"16","key":"13345_CR48","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/jnci\/djh226","volume":"96","author":"M Drosten","year":"2004","unstructured":"Drosten M, Hilken G, B\u00f6ckmann M, R\u00f6dicker F, Mise N, Cranston AN, et al. Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma. J Natl Cancer Inst. 2004;96(16):1231\u20139. https:\/\/doi.org\/10.1093\/jnci\/djh226. [cited 2023 Sep 19].","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"13345_CR49","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3747\/co.26.5539","volume":"26","author":"CM Thomas","year":"2019","unstructured":"Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D. Diagnosis and pathologic characteristics of medullary thyroid carcinoma\u2014review of current guidelines. Curr Oncol. 2019;26(5):338. Available from:\u00a0https:\/\/www.mdpi.com\/1718-7729\/26\/5\/5539 .","journal-title":"Curr Oncol."},{"issue":"1","key":"13345_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mrrev.2012.09.002","volume":"752","author":"G Figlioli","year":"2013","unstructured":"Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res. 2013;752(1):36\u201344.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23059849\/.\u00a0[cited 2023 Sep 20].","journal-title":"Mutat Res."},{"issue":"8","key":"13345_CR51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/138920211798120835","volume":"12","author":"A Taccaliti","year":"2011","unstructured":"Taccaliti A, Silvetti F, Palmonella G, Boscaro M. Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers. Curr Genomics. 2011;12(8):618. Available from:\u00a0https:\/\/www.eurekaselect.com\/article\/20567.","journal-title":"Curr Genomics."},{"key":"13345_CR52","doi-asserted-by":"crossref","unstructured":"Li Y, Luo Z, Wang X, Zhang S, Hei H, Qin J. Design of new drugs for medullary thyroid carcinoma. Front Oncol. 2022;12. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2022.993725\/full.","DOI":"10.3389\/fonc.2022.993725"},{"issue":"7","key":"13345_CR53","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/ERC-21-0368","volume":"29","author":"A Angelousi","year":"2022","unstructured":"Angelousi A, Hayes AR, Chatzellis E, Kaltsas GA, Grossman AB. Metastatic medullary thyroid carcinoma: a new way forward. Endocr Relat Cancer. 2022;29(7):R85-103.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"13345_CR54","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/14737140.2022.2089118","volume":"22","author":"A Wong","year":"2022","unstructured":"Wong A, Nabata K, Wiseman SM. Medullary thyroid carcinoma: a narrative historical review. Expert Rev Anticancer Ther. 2022;22(8):823\u201334.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"13345_CR55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1590\/2359-3997000000267","volume":"61","author":"LMZ Maciel","year":"2017","unstructured":"Maciel LMZ, Magalh\u00e3es PKR. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio. Arch Endocrinol Metab. 2017;61(4):398\u2013402.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28658345\/.\u00a0[cited 2023 Sep 20].","journal-title":"Arch Endocrinol Metab."},{"issue":"3","key":"13345_CR56","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/thy.2020.0206","volume":"31","author":"VF Koehler","year":"2021","unstructured":"Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, et al. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid. 2021;31(3):459\u201369.","journal-title":"Thyroid"},{"issue":"50","key":"13345_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ctrv.2016.09.006","volume":"1","author":"V Ernani","year":"2016","unstructured":"Ernani V, Kumar M, Chen AY, Owonikoko TK. Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev. 2016;1(50):89\u201398.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"13345_CR58","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1349-7006.2009.01484.x","volume":"101","author":"K Koga","year":"2010","unstructured":"Koga K, Hattori Y, Komori M, Narishima R, Yamasaki M, Hakoshima M, et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 2010;101(4):941\u20137.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20704575\/.\u00a0[cited 2023 Sep 20].","journal-title":"Cancer Sci."},{"issue":"5","key":"13345_CR59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/er.2006-0017","volume":"27","author":"JWB De Groot","year":"2006","unstructured":"De Groot JWB, Links TP, Plukker JTM, Lips CJM, Hofstra RMW. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27(5):535\u201360.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16849421\/.\u00a0 [cited 2023 Sep 20].","journal-title":"Endocr Rev."},{"issue":"4","key":"13345_CR60","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67(4):657\u201385.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14665679\/.\u00a0[cited 2023 Sep 20].","journal-title":"Microbiol Mol Biol Rev."},{"issue":"2\u20133","key":"13345_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard L, Rossi JJ. RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2\u20133):75\u201386.","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"13345_CR62","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/jnci\/djh226","volume":"96","author":"M Drosten","year":"2004","unstructured":"Drosten M, Hilken G, B\u00f6ckmann M, R\u00f6dicker F, Mise N, Cranston AN, et al. Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma. J Natl Cancer Inst. 2004;96(16):1231\u20139. https:\/\/doi.org\/10.1093\/jnci\/djh226. [cited 2023 Sep 20].","journal-title":"J Natl Cancer Inst."},{"key":"13345_CR63","doi-asserted-by":"crossref","unstructured":"Kanteti AP, Atiya S, Hein A, Cox JL, Martinez Duarte E. Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast. Case Rep Pathol. 2020;1\u20134 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32528739\/.\u00a0[cited 2023 Sep 20].","DOI":"10.1155\/2020\/6138409"},{"issue":"6","key":"13345_CR64","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00005537-199906000-00033","volume":"109","author":"CZ Bachrati","year":"1999","unstructured":"Bachrati CZ, Pocsai G, Rask\u00f3 I. RET\/PTC fusion gene products in patients suffering from thyroid carcinomas. Laryngoscope. 1999;109(6):1011\u20135.\u00a0Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10369300.\u00a0[cited 2023 Sep 20].","journal-title":"Laryngoscope."},{"issue":"1","key":"13345_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00005537-199701000-00019","volume":"107","author":"A Wirtschafter","year":"1997","unstructured":"Wirtschafter A, Schmidt R, Rosen D, Kundu N, Santoro M, Fusco A, et al. Expression of the RET\/PTC fusion gene as a marker for papillary carcinoma in Hashimoto\u2019s thyroiditis. Laryngoscope. 1997;107(1):95\u2013100.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9001272\/.\u00a0[cited 2023 Sep 20].","journal-title":"Laryngoscope."},{"issue":"12","key":"13345_CR66","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1054\/bjoc.2001.2187","volume":"85","author":"C Mechler","year":"2001","unstructured":"Mechler C, Bounacer A, Suarez H, Saint Frison M, Magois C, Aillet G, et al. Papillary thyroid carcinoma: 6 Cases from 2 families with associated lymphocytic thyroiditis harbouring RET\/PTC rearrangements. Br J Cancer. 2001;85(12):1831\u20137.","journal-title":"Br J Cancer"},{"key":"13345_CR67","doi-asserted-by":"crossref","unstructured":"Gilbert-Sirieix M, Makoukji J, Kimura S, Talbot M, Caillou B, Massaad C, et al. Wnt\/\u03b2-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells. PLoS One. 2011;6(7).\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21814573\/. [cited 2023 Sep 20].","DOI":"10.1371\/journal.pone.0022280"},{"issue":"4","key":"13345_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1677\/JME-09-0024","volume":"43","author":"A Cerrato","year":"2009","unstructured":"Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol. 2009;43(4):143\u201355.\u00a0Available from: https:\/\/jme.bioscientifica.com\/view\/journals\/jme\/43\/4\/143.xml.\u00a0[cited 2023 Sep 20].","journal-title":"J Mol Endocrinol."},{"issue":"4","key":"13345_CR69","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/cas.13172","volume":"108","author":"Y Shikata","year":"2017","unstructured":"Shikata Y, Kiga M, Futamura Y, Aono H, Inoue H, Kawada M, et al. Mitochondrial uncoupler exerts a synthetic lethal effect against \u03b2-catenin mutant tumor cells. Cancer Sci. 2017;108(4):772\u201384.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28107588\/.\u00a0[cited 2023 Sep 18].","journal-title":"Cancer Sci."},{"key":"13345_CR70","doi-asserted-by":"crossref","unstructured":"Trejo-Solis C, Escamilla-Ramirez A, Jimenez-Farfan D, Castillo-Rodriguez RA, Flores-Najera A, Cruz-Salgado A. Crosstalk of the Wnt\/\u03b2-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells. Pharmaceuticals. 2021;14(9). Available from: https:\/\/www.mdpi.com\/1424-8247\/14\/9\/871.","DOI":"10.3390\/ph14090871"},{"key":"13345_CR71","doi-asserted-by":"crossref","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184. Available from:\u00a0https:\/\/www.nature.com\/articles\/nrc3431.","DOI":"10.1038\/nrc3431"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13345-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:03:14Z","timestamp":1734933794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13345"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13345-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1569"}}